The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging.
The dopamine-depleting effects of intracerebroventricularly administered 6-hydroxydopamine (6-OHDA) were studied in young mature (6-8 weeks), older (8-12 months) and aged (18-24 months) mice. No differences were noted between age groups. To rule out the possibility that higher levels of monoamine oxidase (which degrades 6-OHDA) in older animals might be masking an increased sensitivity of older neurons to 6-OHDA, experiments were repeated after treatment with pargyline (50 mg/kg). Again, no differences between age groups were noted. We conclude that aging does not increase the sensitivity of dopaminergic neurons to 6-OHDA.
D000375:Aging / Q000378:metabolism*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D006892:Hydroxydopamines / Q000008:administration & dosage / Q000633:toxicity*; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008995:Monoamine Oxidase / Q000378:metabolism; D016627:Oxidopamine; D010293:Pargyline
D006892:Hydroxydopamines; D016627:Oxidopamine; D010293:Pargyline; D008995:Monoamine Oxidase; D004298:Dopamine